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The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients
with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic
chemotherapy with therapeutic vaccines might increase the eﬃcacy of the treatment. Twenty one patients with metastatic breast
cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50mg of cyclophospamide
orally daily and 2.5mg of methotrexate orally bi-daily), in combination with ﬁve bi-weekly subcutaneous injections of 1mg
of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five
patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression
was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was
18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild.
Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the
treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages
of the administration.
1.Introduction
Chemotherapeutic drugs given at the maximum tolerated
dose (MTD) have had very low impact on the survival of
patients with malignant metastatic diseases, with an increase
of acute and chronic toxicities.
In the last ten years, several studies have demonstrated
that chronic administration of low doses cytotoxic agents
in more frequent schedules (metronomic delivery) was as
eﬀective as MTD regimens, but with reduced toxicity [1, 2].
Angiogenesis plays a central role in local tumor growth
and in the development of distant metastases in breast
cancer.Resultsofpreclinicalstudiessuggestthatangiogenesis
precedes the transformation process from hyperplasia to
neoplasia [3].
Several chemotherapeutic agents, used routinely for
breast cancer treatment, have antiangiogenic activity [4, 5].
While the objective of chemotherapeutic drugs administered
at the MTD is to achieve optimal tumor cell killing, the
highest antiangiogenic activity usually requires a prolonged
exposition of low drug concentrations, as has been demon-
strated in diﬀerent preclinical models [6, 7]. The mechanism
responsible of the anti-angiogenic activity of metronomic
chemotherapy (MC) seems to be the induction of increased
plasmatic levels of trombospondin 1, that is a potent
endothelial angiogenic inhibitor [8].2 International Journal of Breast Cancer
MC can be considered as a variant of “dense-dose”
treatmentwiththediﬀerencethatcumulativedoseofMCcan
be signiﬁcantly lower than MTD-based chemotherapy [9].
MC reduces the level of toxicity and decreases or abolishes
the need of support treatments with growth factors to
accelerate recovery of bone marrow. In spite of having lower
cumulative dose of drug, MC exhibits a superior therapeutic
eﬀectintermsofincreasesurvivalthanconventionalschemes
of MTD [9].
In a previous published study [10], our group showed
that MC with cyclophosphamide and methotrexate pro-
duced clinical responses and survival similar to those
obtained with the schemes conventionally used in the treat-
ment of breast cancer after a ﬁrst line of chemotherapy for
metastaticdisease.Atotalof28patientswereincludedinthat
study, and among them 14 patients demonstrated objective
responses and 8 patients had disease stabilization. Median
time to progression was 3,7 months (2,3–8,7 months), and
median overall survival time was 7,9 months (95% CI, 3,7–
26,2months).Responsedurationwashigherthan12months
in 18,2% of the patients. The most frequently observed
toxicities were grade 2 anemia and leukopenia, which was
observed in 11 patients; grade 2-3 liver toxicity in 6 patients;
and grade 2-3 nausea in 9 patients.
Ontheotherhand,theCenterofMolecularImmunology
(CIM) has reported a new vaccine preparation containing a
murine anti-idiotype monoclonal (MAb) called 1E10 (raco-
tumomab) obtained after immunization of BALB/c mice
with P3 MAb, an antibody that recognizes N-glycolyl
containing-gangliosides, sulphated glycolipids, and antigens
present in melanoma, breast carcinomas, and lung tumours
[11–14]. Preparations containing 1E10 MAb were able to
induce antitumor eﬀects in diﬀerent tumor murine models
[15].
A phase I clinical trial conducted in 15 patients with
advanced breast cancer treated with 1 or 2mg of 1E10-
Alum vaccine every other week for six injections showed
that there were no diﬀerences between the two levels of
dose tested in relation to toxicity and immunogenicity. No
evidence of serious or unexpected eﬀects was observed. The
median survival time of all treated patients was 19 months.
For patients that received more than six doses of the anti-
idiotype vaccine the median survival time was 24 months
(95% conﬁdence interval, 20.61–27.39 months). Two of the
immunized patients remained with stable disease for more
than 24 months [16].
More recently a preclinical study was carried out with the
main objective to determine the antitumor eﬀect of 1E10-
Alum vaccine coadministered with low dose of cyclophos-
phamide in a murine mammary carcinoma model, based on
their potentially shared antiangiogenic properties and/or a
complementary proapoptotic eﬀect by 1E10-Alum vaccine.
The results of the study showed that the combination
enhanced the eﬃcacy of chemotherapy or immunotherapy
alone in the F3II carcinoma model [17].
Here, we report the results of an exploratory study in
metastatic breast cancer patients in which we evaluated the
safety proﬁle and the preliminary clinical outcome of the use
of metronomic chemotherapy with cyclophosphamide and
methotrexate in combination with 1E10-Alum vaccine.
2.MaterialandMethods
2.1. Patients. From February 2007 to February 2009, the
Oncology Services of “Hermanos Ameijeiras” (HA) hos-
pital (HAH), from Havana, Cuba and “Jos´ eR .L ´ opez
Tabranes” (JRLT) hospital from Matanzas, Cuba carried out
a prospective exploratory study that incorporated metro-
nomic chemotherapy and 1E10-Alum vaccination to treat
female patients with histologically conﬁrmed metastatic
breast cancer in progression, who had received at least one
line of chemotherapy for their metastatic disease. Other
eligibility criteria included Eastern Cooperative Oncology
group (ECOG) performance ≤2 or Karnofsky index ≥60%,
age ≥18 years and <80, normal haematopoietic, hepatic
and renal functions, and life expectancy higher than 6
months, and adequate bone marrow reserve deﬁned as
leukocyte >3,000/μl, neutrophiles >1,500/μl( m m 3); platelets
>100,000/μl( m m 3); adequate renal function (serum cre-
atinine >60mL/min/1.73m2) and hepatic function (total
bilirubin and ALAT/ASAT ≤2.5LSN). The most important
exclusion criteria included the presence of brain metastases,
pregnancy, or lactation, serious chronic diseases and active
infections. Patients who had received treatment with MAbs
or other biological modiﬁers of the immune response were
not included.
Each patient included in this study gave a written
informed consent. The study was approved by the Ethical
Committees of the hospitals.
2.2. Anti-Idiotype 1E10 MAb for the Clinical Trial. 1E10 MAb
was puriﬁed from mouse ascites in the Good Manufactur-
ing Practice (GMP) facilities of the Center of Molecular
Immunology. Puriﬁcation of 1E10 MAb was performed
by DEAE-exchange chromatography followed by aﬃnity
chromatography on Protein A-CL Sepharose 4B column
and size exclusion chromatography on Sephadex G-25
column (Amersham Pharmacia Biotech, Uppsala, Sweden).
The purity of the isolated immunoglobulin was more than
97% as determined by SDS-PAGE, high-pressure liquid
chromatography, and isoelectric focusing. The vaccine was
produced in accordance with the Good Manufacturing
Practice guidelines and certiﬁed by the Quality Control
DepartmentoftheCenterofMolecularImmunology.Brieﬂy,
sterile puriﬁed 1E10 MAb was aseptically mixed at a ﬁnal
concentration of 1mg/mL with 5mg/mL of aluminum
hydroxide as adjuvant (Superfos Biosector, Frederikssund,
Denmark). The mixture was gently stirred for 3 hours at
room temperature. The aluminum hydroxide-precipitated
MAb (1E10-Alum vaccine) was aliquoted into pyrogen-free,
sterile glass vials and stored at 4◦C until use. The ﬁnal
product was tested for sterility, pyrogenicity, and general
safety in mice and guinea pigs before use, according to the
United States Pharmacopoeia and to British Pharmacopoeia.
2.3. Treatment Schedule. Metronomic chemotherapy con-
sisted in oral administration of cyclophosphamide at a doseInternational Journal of Breast Cancer 3
of 50mg once a day (after breakfast) and methotrexate at
a dose of 2.5mg twice a day on days 2 and 4 every week
(08:00, 17:00h). Antiemetic prophylaxis was performed
with metoclopramide (10mg/orally), thirty minutes before
chemotherapy.
1E10-Alum vaccine (1mg/dose) was administered intra-
dermally. Five doses were administered biweekly (2 months
induction phase), followed by 10 monthly doses (mainte-
nance phase).
Both treatments were maintained until patients had un-
acceptable toxicity or worsening of the performance status.
2.4. Evaluation before and during Treatment. Baseline eval-
uation included medical and smoking history, physical
examination, vital signs, performancestatus,complete blood
cell count and blood biochemistry, and plain chest radio-
graphic examination, abdominal ultrasound, bone scan
and selective radiographic examination and/or CT and/or
MRI (depending on each case), breast ultrasound, and
mammography (in case of need). Follow-up evaluation was
done every 28 days before chemotherapy administration and
included patients physical exam, complete blood count, and
biochemistry. Imaging studies were performed according
to patients symptoms, and if there were not any, every 3
months.
The primary end point of this study was safety. Adverse
events were evaluated according to the NCI Common
Toxicity Criteria (version 3.0). In the evaluation of toxicity,
only the greatest degree of toxicity was gathered and
complications were recorded for each patient.
The secondary end point of the study was the evaluation
of preliminary eﬃcacy in terms of response rate, time to
progression, and overall survival. Response evaluation was
performed according to Response Evaluation Criteria In
Solid Tumors (RECIST, version 1.0), beginning at 4 weeks of
starting treatment. Time to progression was calculated from
thedateofstartingchemotherapytodateoftheconﬁrmation
of progression or local or distant recurrence. Overall survival
wasthetimebetweenthebeginningofchemotherapyandthe
date of death or the date at which patients were last known to
be alive. Progression and survival times were estimated using
the Kaplan-Meier method via the SPSS Program (version
10.0).
3. Results
Twenty-one patients were included in the study from
February 2007 to February 2009. Median age was 46 years
(range 35–82 years). More than 50% of the patients had a
premenopausal status. All patients had measurable disease.
The higher percentage of tumors was classiﬁed as estrogen
receptor-positive and HER-2 receptor-negative. Less than
10% of the patients had a single metastatic site. The sites
of metastases were, in decreasing order, bone, lung, skin,
soft tissue, liver, and others (Table 1). The median number
of previous chemotherapy lines received by the patients was
2 (range1–3). Nineteen patients had progressive metastatic
disease, while two patients had stage IV disease at the
Table 1: Characteristics of patients included in the study.
Characteristic No. of
patients
Percent of total
patients (%)
Median of age (range) 46 (35–82)
Menopausal status
(pre/post) 11/10 52,4/47,6
Estradiol Receptor
Negative 5 23,8
Positive 9 42,9
Unknown 7 33,3
HER 2 Receptor
Negative 13 61,9
Positive 1 4,8
Unknown 7 7
Patients by number of
metastatic sites (1/2/>2) 2/11/8 9,5/52,4/38,1
Metastases localization
(n = 50)
(i) Lung/Pleura 10 47,6
(ii) Liver 6 28,6
(iii) Skin 7 33,3
(iv) Soft tissue 6 28,6
(v) Bone 12 57,1
(vi) Lymph nodes 5 23,8
(vii) Others 3 14,3
moment of diagnosis. The fourteen patients included in the
HA hospital had received at least two lines of conventional
chemotherapy treatment for their metastatic disease, while
thesevenpatientsincludedbytheJRLThospitalreceivedonly
one line of chemotherapy.
All patients were assessed for toxicity and the adverse
events observed are shown in Table 2.I nt o t a l ,4 0a d v e r s e
events were reported and most of them were classiﬁed as
grade 1, according to the NCI Common Toxicity Criteria
(version 3.0). Over 50% of side eﬀects were pain at the site
of injection. Four patients presented grade 2 toxicities: one
patient had anemia, two patients had nausea and vomiting,
and in one patient an increase in transaminase values was
detected. Only one patient had to interrupt treatment due to
grade 3 nausea and vomiting caused by the deterioration of
general condition and progression of liver metastases.
Although this was an exploratory study, a preliminary
evaluation of the clinical outcome was performed after
patients were treated with the combination of MC and anti-
idiotype vaccination (Table 3). Objective response (complete
and partial responses) was demonstrated in 5 patients
(23,8%), and the disease was stabilized in 8 patients (38,1%).
Thus, the disease control rate was 61,9% (CR+PR+SD) after
treatment. Regarding the patients with stage IV disease,
one achieved complete remission, and then underwent local
surgery of the breast (modiﬁed radical mastectomy). In the
second patient the disease, was stabilized.
The median time to disease progression was 9.82 months
(CI 95%, 3,8–15,9 months), while the median survival time4 International Journal of Breast Cancer
Table 2: Summary of the adverse events.
Event
Grade
01234
N o .%N o .%N o .%N o .%N o .%
Leukopenia 19 90,5 2 9,5 0 0 0 0 0 0
N e u t r o p e n i a 2 1 1 0 0 00000000
Anemia 18 85,7 2 9,5 1 4,8 0 0 0 0
T h r o m b o c y t o p e n i a 2 1 1 0 0 00000000
Nausea/Vomiting 16 76,2 2 9,5 2 9,5 1 4,8 0 0
Transaminases 19 90,5 1 4,8 1 4,8 0 0 0 0
Gastric pain 19 90,5 2 9,5 0 0 0 0 0 0
M u c o s i t i s 2 1 1 0 0 00000000
Fever 19 90,5 2 9,5 0 0 0 0 0 0
Myalgia 18 85,7 3 14,3 0 0 0 0 0 0
P a i n a t t h e i n j e c t i o n s i t e 00 2 1 1 0 0 000000
Total 191 82,7 35 15,2 4 1,7 1 0,4 0 0
Table 3: Eﬃcacy evaluation after the treatment of MBC patients
with MCT combined with 1E10 Aluminum/hydroxide vaccine.
Clinical response evaluation
MCT+1E10 vaccine
n = 21 %
CR 2 9,5
PR 3 14,3
SD 8 38,1
PD 8 38,1
TTP (95% CI, months) 9,82 (3,8–15,9)
OS (95% CI, months) 12,93 (7,8–19,9)
Response duration >12 months 10 76,9%
was 12.93 months (CI 95%, 7,8–19,9 months). The median
duration of the response (CR+PR+SD) was 18,43 months
(12,20–24,10 months), being higher than 12 months in 10
of the responding patients (76,9%).
4. Discussion
In the historical development of antineoplastic agents, it has
been postulated that the cytotoxic eﬀect on tumor cells of
these agents is related to the dose administered and that
this is the main cause of antitumor eﬃcacy [18]. In fact,
the principle of dose intensity is supported by experimental
studies, where a small increment in drug dose can increase
tumour cell death. This aspect of dose intensity and eﬃcacy
of tumour cell death in advanced breast cancer is still more
controversial, due to the high heterogeneity of tumour breast
cells, drug interactions, and the large number of prognostic
factors that might impact in the outcome of treated breast
cancer patients [19].
Some studies have demonstrated that cyclophosphamide
whenadministered atMTD,causesendothelialcellapoptosis
in the new formed tumor microvessels [20]. A detailed
temporal analysis showed that endothelial cells were the
ﬁrst in the tumor to undergo apoptosis; however, this
antiangiogenic eﬀect does not translate into therapeutical
beneﬁt,becausemostofthedamageinthetumorvasculature
isrepairedduringtherestperiodsbetweenthechemotherapy
cycles [21, 22]. In contrast, MC which involves the frequent
administration of low doses of cytotoxic drugs avoids dose-
limiting adverse eﬀects and then the need of rest periods,
allowing the continue exposition of tumor endothelial cells
to the actions of the cytotoxic drugs. For these reasons,
chemotherapy in low doses has been evaluated in combina-
tion with other antineoplastic agents to minimize secundary
eﬀectsandtoproducesynergicandadditivebeneﬁts[23,24].
In a recently published preclinical study [17], the treat-
ment with a low-dose of cyclophosphamide had not eﬀect in
mice bearing a mammary tumor while a limited antitumor
eﬀect was induced by a single 1E10-Alum vaccine sub-
cutaneous injection. However, the coadministration of the
anti-idiotype vaccine with a low dose of cyclophosphamide
signiﬁcantly reduced the F3II mammary carcinoma growth.
The therapeutic eﬀect of the chemoimmunotherapy combi-
nation was associated to the increment of T cells inﬁltrating
metastases, the reduction of new blood vessels formation
and the increase of apoptotic tumor cells. These results
support that the increase in apoptosis might contribute to
tumor control [24] and that the antiangiogenic eﬃcacy of a
particular therapy might be increased with a combination of
treatments [25–27].
In addition, it is known that metronomic regimen of
cyclophosphamidedoesnotonlyreducetumorangiogenesis,
but also selectively depletes immunosuppressive regulatory
T cells allowing tumor progression control and facilitating
antitumor immunotherapy [28]. The potential eﬀect of the
CTinthedepletionofregulatoryTcellscouldalsocontribute
to increase the antitumor eﬀects induced by 1E10-Alum
vaccine in murine tumor models [17].
On the other hand, in a previous study 1E10-Alum treat-
mentdemonstratedtoinducenotonlyhumoral,butalsocel-
lular immune responses in metastatic breast cancer patientsInternational Journal of Breast Cancer 5
[29]. Combined therapies that include this anti-idiotype
vaccine might stimulate in cancer patients immunological
mechanisms able to ﬁght against tumor and its dissemina-
tion.
This is the ﬁrst report in the use of an anti-idiotype
vaccine related to NeuGc-containing gangliosides in combi-
nation with MC for the treatment of metastatic breast cancer
patients.
In the present study, although the patients were repeat-
edly treated with metronomic doses of cyclophophamide
and methotrexate in combination with 1E10-Alum vaccine,
only a low rate of side eﬀects was observed, and these side
eﬀects were the same observed in previous reports using MC
or anti-idiotype vaccine therapy in breast cancer patients
[10, 16, 29].
The objective response rate was lower in this study than
inthepreviousstudyconductedbyourgroupusingonlyMC
[10](14,3%versus46,4%).Thisresultcouldberelatedtothe
fact that, in comparison with the previous study, most of the
patients included in the present study (66,6%) had received
at least two therapeutic lines for metastatic disease and more
than 90% had two or more metastatic sites. Nevertheless it
is noteworthy that the median time to progression and the
overall survival of the patients who entered this study and
received MC and 1E10-Alum therapy were superior to the
ones previously reported for the patients who received MC
alone (9,82 versus 3,7 months and 12,93 versus 7,9 months,
resp.).
Other encouraging result of the present study using the
combined therapy of MC and the anti-idiotype vaccine was
that the percentage of the patients who reached a response
duration higher than 12 months was superior than the
one reported when MC was used alone [10] (76,9% versus
18,2%).
In conclusion, the results of this study suggest that oral
administration of low doses of cyclophosphamide and me-
thotrexate, combined to immunotherapy with 1E10-Alum
seems to prolong survival of a subgroup of patients with
metastatic breast cancer with low toxicity. A randomized
Phase II clinical trial will start soon where the clinical beneﬁt
of the combination of 1E10-Alum vaccine with MC in
comparison with MC treatment alone will be evaluated.
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